Kidney Cancer: New Concepts in Evaluation and Management 

Supported by an educational grant from

This course will review the significant progress that has occurred during the past decade in our understanding of the biology, evaluation and management of RCC. The heterogenous nature of this disease, the limitations of the current TNM (Tumor, Node, Metastasis) staging system and new multifactorial prognostic algorithms will be discussed. The role of observation, total vs. partial nephrectomy and new forms of focal ablative therapy for localized RCC will be reviewed. The status of multimodality therapy for metastatic disease, incorporating targeted molecular drugs, will be discussed. Data from the peer-reviewed literature will be analyzed to provide valid outcome-based comparisons of both established and developmental treatment modalities for localized and advanced disease. Objectives: After attending this course, participants should be able to: review the histologic, molecular and clinical characteristics of RCC outline the natural history of RCC and prognostic variables affecting outcome discuss the available treatments for localized RCC, including active surveillance, open vs. laparoscopic total and partial nephrectomy, and energy-based tumor ablation describe the categories and emerging roles of targeted molecular therapy in metastatic RCC assess the contemporary role of neoadjuvant systemic therapy, cytoreductive nephrectomy and metastasectomy in metastatic RCC

If you wish to apply for CME for these lectures, please log in first.